Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines

European Journal of Cancer

Volumn 35, Issue 5, 1999, Pages 796-807

  Tolis, C ^a   Peters, G J ^a   Ferreira, C G ^a   Pinedo, H M ^a   Giaccone, G ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Apoptosis; Cell cycle; Gemcitabine; Lung cancer; Topotecan

Indexed keywords

DNA; GEMCITABINE; PROTEIN P21; PROTEIN P53; TOPOTECAN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG CANCER; PRIORITY JOURNAL; TIME;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; TOPOTECAN; TUMOR CELLS, CULTURED;

EID: 0032998028     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00425-0     Document Type: Article

References (61)

1. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science. 267:1995;1456-1462.
2. Di Leonardo L.A., Linke S.P., Clarkin K., Wahl G.M. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev. 8:1994;2540-2551.
3. Kagawa S., Fujiwara T., Hizuta A., et al. p53 expression overcomes p21WAF1/CIP1-mediated G1 arrest and induces apoptosis in human cancer cells. Oncogene. 15:1997;1903-1909.
4. Caelles C., Helmberg A., Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes (see comments). Nature. 370:1994;220-223.
5. Fan S., el-Deiry W.S., Bae I., et al. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res. 54:1994;5824-5830.
6. Haupt Y., Rowan S., Shaulian E., Kazaz A., Vousden K., Oren M. p53 mediated apoptosis in HeLa cells: transcription dependent and independent mechanisms. Leukemia. 11:(Suppl. 3):1997;337-339.
7. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science. 253:1991;49-53.
8. Hollstein M., Shomer B., Greenblatt M., et al. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic. Acids. Res. 24:1996;141-146.
9. Kovach J.S., Hartmann A., Blaszyk H., Cunningham J., Schaid D., Sommer S.S. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc. Natl. Acad. Sci. USA. 93:1996;1093-1096.
10. Takahashi T., Suzuki H., Hida T., Sekido Y., Ariyoshi Y., Ueda R. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene. 6:1991;1775-1778.
11. Casey G., Lopez M.E., Ramos J.C., et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene. 13:1996;1971-1981.
12. Ardizzoni A., Hansen H., Dombernowsky P., et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J. Clin. Oncol. 15:1997;2090-2096.
13. Thatcher N., Hopwood P., Anderson H. Improving quality of life in patients with non-small cell lung cancer: research experience with gemcitabine. Eur. J. Cancer. 33:(Suppl. 1):1997;S8-S13.
14. Binaschi M., Zunino F., Capranico G. Mechanism of action of DNA topoisomerase inhibitors. Stem. Cells (Dayt). 13:1995;369-379.
15. Okamoto-Kubo S., Nishio K., Heike Y., Yoshida M., Ohmori T., Saijo N. Apoptosis induced by etoposide in small-cell lung cancer cell lines. Cancer Chemother. Pharmacol. 33:1994;385-390.
16. Fujiwara T., Grimm E.A., Mukhopadhyay T., Zhang W.W., Owen-Schaub L.B., Roth J.A. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 54:1994;2287-2291.
17. Kalemkerian G.P., Slusher R., Ramalingam S., Gadgeel S., Mabry M. Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines (see comments). J. Natl. Cancer Inst. 87:1995;1674-1680.
18. Shimizu T., Pommier Y. Camptothecin-induced apoptosis in p53-null human leukemia HL60 cells and their isolated nuclei: effects of the protease inhibitors Z-VAD-fmk and dichloroisocoumarin suggest an involvement of both caspases and serine proteases. Leukemia. 11:1997;1238-1244.
19. Ruiz van Haperen V.W., Veerman G., Vermorken J.B., Peters G.J. 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem. Pharmacol. 46:1993;762-766.
20. Winter S.F., Minna J.D., Johnson B.E., Takahashi T., Gazdar A.F., Carbone D.P. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res. 52:1992;4168-4174.
21. Campling B.G., Pym J., Baker H.M., Cole S.P., Lam Y.M. Chemosensitivity testing of small cell lung cancer using the MTT assay. Br. J. Cancer. 63:1991;75-83.
22. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods. 139:1991;271-279.
23. Kerr J.F., Winterford C.M., Harmon B.V. Apoptosis. Its significance in cancer and cancer therapy. Cancer. 73:1994;2013-2026, 3108.
24. Gorczyca W., Gong J., Darzynkiewicz Z. Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res. 53:1993;1945-1951.
25. Brown S.B., Bailey K., Savill J. Actin is cleaved during constitutive apoptosis. Biochem. J. 323:1997;233-237.
26. Levee M.G., Dabrowska M.I., Lelli J.L.J., Hinshaw D.B. Actin polymerization and depolymerization during apoptosis in HL-60 cells. Am. J. Physiol. 271:1996;C1981-C1992.
27. Liu T.J., el-Naggar A.K., McDonnell T.J., et al. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res. 55:1995;3117-3122.
28. Gomez-Manzano C., Fueyo J., Kyritsis A.P., et al. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res. 56:1996;694-699.
29. Peters G.J., Bergman A.M., Ruiz van Haperen V.W., Veerman G., Kuiper C.M., Braakhuis B.J. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin. Oncol. 22:1995;72-79.
30. Ardizzoni A., Hansen H., Dombernowsky P., et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. J. Clin. Oncol. 15:1997;2090-2096.
31. ten Bokkel Huinink W., Carmichael J., Armstrong D., Gordon A., Malfetano J. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma. Semin. Oncol. 24:1997;S5-S25.
32. Bible K.C., Kaufmann S.H. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res. 57:1997;3375-3380.
33. Bonner J.A., Kozelsky T.F. The significance of the sequence of administration of topotecan and etoposide. Cancer Chemother. Pharmacol. 39:1996;109-112.
34. Whitacre C.M., Zborowska E., Gordon N.H., Mackay W., Berger N.A. Topotecan increases topoisomerase II alpha levels and sensitivity to treatment with etoposide in schedule-dependent process. Cancer Res. 57:1997;1425-1428.
35. Lamond J.P., Mehta M.P., Boothman D.A. The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation. J. Neurooncol. 30:1996;1-6.
36. Kaufmann S.H., Peereboom D., Buckwalter C.A., et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines (see comments). J. Natl. Cancer Inst. 88:1996;734-741.
37. Carmichael J., Allerheiligen S., Walling J. A phase I study of gemcitabine and carboplatin in non-small cell lung cancer. Semin. Oncol. 23:1996;55-59.
38. Giaccone G. New drugs in non-small cell lung cancer. An overview. Lung Cancer. 12:(Suppl. 1):1995;S155-S162.
39. Seiter K., Feldman E.J., Halicka H.D., et al. Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia. J. Clin. Oncol. 15:1997;44-51.
40. Perez-Soler R., Fossella F.V., Glisson B.S., et al. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J. Clin. Oncol. 14:1996;503-513.
41. van Moorsel C., Veerman G., Bergman A.M., et al. Combination chemotherapy studies with gemcitabine. Semin. Oncol. 24:1997;S7-S23.
42. Crino L., Scagliotti G., Marangolo M., et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J. Clin. Oncol. 15:1997;297-303.
43. Pedersen A.G., Kanzawa F., Saijo N., et al. Phase I studies of gemcitabine combined with carboplatin or paclitaxel. Semin. Oncol. 24:1997;S7-S68.
44. Shewach D.S., Lawrence T.S. Gemcitabine and radiosensitization in human tumor cells. Invest. New Drugs. 14:1996;257-263.
45. McGinn C.J., Shewach D.S., Lawrence T.S. Radiosensitizing nucleosides. J. Natl. Cancer Inst. 88:1996;1193-1203.
46. Huang P., Plunkett W. Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother. Pharmacol. 36:1995;181-188.
47. Santini V., Bernabei A., Gozzini A., et al. Apoptotic and antiproliferative effects of gemcitabine and gemcitabine plus Ara-C on blast cells from patients with blast crisis chronic myeloproliferative disorders. Haematologica. 82:1997;11-15.
48. Traganos F., Seiter K., Feldman E., Halicka H.D., Darzynkiewicz Z. Induction of apoptosis by camptothecin and topotecan. Ann. N. Y. Acad. Sci. 803:1996;101-110.
49. Planchon S.M., Wuerzberger S., Frydman B., et al. Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response. Cancer Res. 55:1995;3706-3711.
50. Holm C., Covey J.M., Kerrigan D., Pommier Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res. 49:1989;6365-6368.
51. Seiter K., Feldman E.J., Halicka H.D., et al. Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia. J. Clin. Oncol. 15:1997;44-51.
52. Jonsson E., Fridborg H., Csoka K., et al. Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients. Br. J. Cancer. 76:1997;211-219.
53. Darzynkiewicz Z., Juan G., Li X., Gorczyca W., Murakami T., Traganos F. Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry. 27:1997;1-20.
54. Lanni J.S., Lowe S.W., Licitra E.J., Liu J.O., Jacks T. p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc. Natl. Acad. Sci. USA. 94:1997;9679-9683.
55. Midis G.P., Shen Y., Owen-Schaub L.B. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res. 56:1996;3870-3874.
56. el-Deiry W.S., Tokino T., Velculescu V.E., et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
57. el-Deiry W.S., Harper J.W., O'Connor P.M., et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54:1994;1169-1174.
58. Brugarolas J., Chandrasekaran C., Gordon J.I., Beach D., Jacks T., Hannon G.J. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature. 377:1995;552-557.
59. Agarwal M.L., Agarwal A., Taylor W.R., Stark G.R. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. USA. 92:1995;8493-8497.
60. Stewart N., Hicks G.G., Paraskevas F., Mowat M. Evidence for a second cell cycle block at G2/M by p53. Oncogene. 10:1995;109-115.
61. Attardi L.D., Lowe S.W., Brugarolas J., Jacks T. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J. 15:1996;3693-3701.